292 related articles for article (PubMed ID: 28159681)
1. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
4. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
[TBL] [Abstract][Full Text] [Related]
5. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
7. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract][Full Text] [Related]
8. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
[TBL] [Abstract][Full Text] [Related]
10. Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.
Shah K; Moharram SA; Kazi JU
Clin Epigenetics; 2018; 10():83. PubMed ID: 29951132
[TBL] [Abstract][Full Text] [Related]
11. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
12. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
13. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
14. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
16. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.
Venkatesan AM; Chen Z; dos Santos O; Dehnhardt C; Santos ED; Ayral-Kaloustian S; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Chaudhary I; Mansour TS
Bioorg Med Chem Lett; 2010 Oct; 20(19):5869-73. PubMed ID: 20797855
[TBL] [Abstract][Full Text] [Related]
17. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
[TBL] [Abstract][Full Text] [Related]
18. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
[TBL] [Abstract][Full Text] [Related]
20. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
